BRAF

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Conditional, Patient, PFS, SAN, NSCLC, CAB, Ipilimumab, PD-1, ASCO, Poster, Carcinoma, Society, Observation, BRAF, Therapy, DLT, Nivolumab, Annual general meeting, Pharmaceutical industry

SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced expanded data at an upcoming presentation entitled, “Phase 1 study of evalstotug (BA3071), an anti-CTLA-4 Conditionally Active Biologic, in combination with nivolumab in advanced solid tumors”, demonstrating confirmed responses with a potentially differentiated tolerability profile with the Company’s novel, conditionally active anti-CTLA-4 agent, evalstotug, in combination with anti-PD-1 therapy. The poster will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois on Saturday, June 1, 2024.

Key Points: 
  • The poster will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois on Saturday, June 1, 2024.
  • “Given the emerging clinical profile observed, we believe evalstotug has the potential to be best-in-class CTLA-4 antibody and holds the promise to be used as often as a PD-1 inhibitor,” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. “Strikingly, we have observed prolonged PFS of greater than 10 months and confirmed responses at high doses (350 mg), of evalstotug, suggesting increased exposure of CTLA-4 blockade in combination with PD-1 inhibition drives clinical benefit.
  • We continue to enroll in the Phase 2 first-line melanoma and mutated NSCLC combination cohorts at the 700 mg flat dose and we anticipate moving to the 1 gram flat dose in June following clearance of the DLT observation period and remain on track for monotherapy and combination data readouts later this year.
  • We anticipate enabling a Phase 3 trial of evalstotug in first-line metastatic or unresectable BRAF-mutated melanoma in the second half of this year.

Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024

Retrieved on: 
torsdag, maj 23, 2024
Immune tolerance, Prognosis, Master, ILT4, Flow cytometry, Pembrolizumab, Anemia, WT, HPV, Colorectal cancer, NK, University, Clinical trial, PFS, Therapy, Neoplasm, Disease, EGFR, Safety, SAN, Head, ILT2, Irinotecan, PD-1, Growth, Bevacizumab, Cancer, Incidence, ASCO, Associate, MHC, Consultant, Woman, Society, Fatigue, BRAF, Cetuximab, Tizona, Immunotherapy, Oxaliplatin, DCR, Combination therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held, clinical-stage company developing cancer immunotherapies, today announced first-in-human Phase 1b clinical data of TTX-080, a novel, first-in-class, antibody targeting HLA-G, in patients with metastatic colorectal cancer (mCRC) and locally advanced/metastatic head and neck squamous cell carcinoma (mHNSCC). The preliminary data will be presented during a poster session on June 1, 2024, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago, IL.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held, clinical-stage company developing cancer immunotherapies, today announced first-in-human Phase 1b clinical data of TTX-080, a novel, first-in-class, antibody targeting HLA-G, in patients with metastatic colorectal cancer (mCRC) and locally advanced/metastatic head and neck squamous cell carcinoma (mHNSCC).
  • The preliminary data will be presented during a poster session on June 1, 2024, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago, IL.
  • “Metastatic colorectal cancer is a global health issue, affecting men and women equally and with rising incidence among young adults.
  • “These Phase 1b clinical results boost our confidence that TTX-080 in combination with cetuximab may improve clinical outcomes in patients with biomarker-defined advanced colorectal cancer and head and neck squamous cell carcinoma,” said Swami Murugappan, M.D., Ph.D., Consulting Chief Medical Officer at Tizona Therapeutics.

BrightSpring Health Services Announces Onco360® Was Selected as National Pharmacy Partner for OJEMDA™

Retrieved on: 
måndag, maj 20, 2024
Insurance, Day One, Patient, Health care, Brain, FDA, Pharmacy, Health, Cancer, LGG, BRAF, BRAF V600, Central nervous system, Pharmaceutical industry

LOUISVILLE, Ky., May 20, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that its company, Onco360®, one of the nation’s largest independent oncology pharmacies, is being selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA™, a cutting-edge treatment for children diagnosed with certain central nervous system tumors.

Key Points: 
  • LOUISVILLE, Ky., May 20, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that its company, Onco360®, one of the nation’s largest independent oncology pharmacies, is being selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA™, a cutting-edge treatment for children diagnosed with certain central nervous system tumors.
  • LGG is the most common central nervous system tumor in children, representing 30% of pediatric brain tumors.
  • BRAF is the most commonly altered gene in pediatric LGG, as 75% of patients have BRAF alterations.
  • We’re proud to partner with Day One Biopharmaceuticals to become a specialty provider for OJEMDA™,” said Benito Fernandez, Chief Commercial Officer at Onco360®.

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Retrieved on: 
tisdag, maj 14, 2024
Conditional, Patient, Pembrolizumab, Neck, SCCHN, FDA, IND, UPS, Anticipation, EGFR, Head, SAN, NSCLC, ADC, CAB, PD-1, Nextgen, Neoplasm, PR, Observation, Research, BRAF, Therapy, G&A, Webcast, DLT, Pharmaceutical industry

Research and development (R&D) expenses were $18.9 million for the quarter ended March 31, 2024 compared to $21.7 million for the same quarter in 2023.

Key Points: 
  • Research and development (R&D) expenses were $18.9 million for the quarter ended March 31, 2024 compared to $21.7 million for the same quarter in 2023.
  • General and administrative (G&A) expenses were $5.6 million for the quarter ended March 31, 2024 compared to $7.2 million for the same quarter in 2023.
  • Net loss for the quarter ended March 31, 2024 was $23.2 million compared to a net loss of $27.5 million for the same quarter in 2023.
  • Cash used for the quarter ended March 31, 2024 included approximately $5.0 million in annual payments that typically only occur during our first fiscal quarter.

$12.498 Billion Companion Diagnostics Markets - Global and Regional Analysis and Forecasts, 2019-2022 & 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
tisdag, maj 21, 2024
Health, Oncology, Medical Devices, Patient, Real-time, Hospital, Region, Laboratory, Prevalence, Single-nucleotide polymorphism, Diagnosis, Lung cancer, Safety, EGFR, Breast cancer, NSCLC, Growth, Cancer, Biomarker, Gene, Reference, ALK, BRAF, Environment, Biotechnology, ROS1, PCR, Medical device

The "Companion Diagnostics Market - A Global and Regional Analysis: Focus on Application, End User, Technology, and Region - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Companion Diagnostics Market - A Global and Regional Analysis: Focus on Application, End User, Technology, and Region - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the companion diagnostics market is driven by the rising prevalence of cancer cases, increasing product approvals in the field of companion diagnostics, and advancing biomedical imaging as the driving force for precision medicine's companion diagnostics.
  • The North America region is expected to hold a significant share of the global companion diagnostics market for several reasons.
  • As a result, these facilities handle a large volume of diagnostic testing, providing economies of scale and driving demand for companion diagnostics.

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Retrieved on: 
torsdag, maj 9, 2024
Cream, CVR, Sale, FDA, BRAF V600, Organon, NDA, Food, Compugen, Department of Defence, Economics, Female, BRAF, PDUFA, Blue Owl Capital, Patient, Bayer, Acquisition, Share repurchase, Food and Drug Administration, Defense, Pharmaceutical industry

EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2024 financial results and highlighted recent activities.

Key Points: 
  • Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib);
    EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2024 financial results and highlighted recent activities.
  • XOMA receives 100 percent of the DSUVIA® economics until a threshold is achieved; thereafter, XOMA retains the 15 percent royalty associated with DSUVIA® commercial sales.
  • The 75 percent royalties from Department of Defense purchases and remaining milestone payments will be shared equally between XOMA and Talphera.
  • Dosed first patient in its Phase 3 trial of RZ358; XOMA earned a $5.0 million milestone associated with the event.

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
torsdag, maj 9, 2024
Diamond, FDA, Cancer, Foundation Medicine, Mutation, Investment, HGG, Food, Research, Lung cancer, GBM, Development, Administration, ASCO, TKI, Helmy Eltoukhy, BRAF, Patient, Society, G&A, AACR, Annual general meeting, Prevalence, NRAS, Pharmaceutical industry

Cash Position: Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents, and investments compared to $131.4 million as of December 31, 2023.

Key Points: 
  • Cash Position: Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents, and investments compared to $131.4 million as of December 31, 2023.
  • Net cash used in operations was $21.2 million for the first quarter of 2024 compared to $20.0 million for the first quarter of 2023.
  • Net Loss: Net loss for the first quarter of 2024 was $18.2 million, as compared to $20.9 million for the same period in 2023.
  • Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents and investments which the Company believes is sufficient to fund its anticipated operating expenses and capital expenditure requirements into the third quarter of 2025.

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

Retrieved on: 
onsdag, maj 8, 2024
Mutation, Safety, Pembrolizumab, Research, Asian literature, CRC, RAS, SHP2, Initiation, Trial of the century, Disclosure, PDAC, BRAF, Patient, SOC, Neoplasm, NRAS, AACR, Clinical trial, Sanofi, G13, GAAP, Lung cancer, Pharmaceutical industry

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress.

Key Points: 
  • REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress.
  • The company continues making progress on its 2024 development priorities:
    Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials.
  • Revenue: Total revenue was zero for the quarter ended March 31, 2024, compared to $7.0 million for the quarter ended March 31, 2023.
  • Revolution Medicines will host a webcast this afternoon, May 8, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
onsdag, maj 8, 2024
Sale, Congress, Dexamethasone, Merck Group, Research and development, Security (finance), Colorectal cancer, Hematology, Research, Therapy, Finance, CRC, ESMO, ATM, Administration, Roche, Public expenditure, BRAF, Completeness, Cancer, Patient, NHL, Melanoma, AACR, Clinical trial, Merck, CCCC, G&A, Lung cancer, Pharmaceutical industry

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the first quarter ended March 31, 2024, as well as recent business highlights.

Key Points: 
  • Revenue: Total revenue for the first quarter of 2024 was $3.0 million, compared to $3.8 million for the first quarter of 2023.
  • General and Administrative (G&A) Expense: G&A expense, net of a one-time $0.5 million restructuring charge, was $10.3 million for the first quarter of 2024.
  • Net Loss and Net Loss per Share: Net loss for the first quarter of 2024 was $28.4 million, compared to $34.8 million for the first quarter of 2023.
  • Net loss per share for the first quarter of 2024 was $0.41 compared to $0.71 for the first quarter of 2023.

Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress

Retrieved on: 
tisdag, maj 7, 2024
Cancer, Safety, Uterine serous carcinoma, Research, Depreciation, Medication, Osteosarcoma, AML, Development, Administration, ASCO, Therapy, BRAF, ADC, Patient, Society, PROC, WEE1, USC, AACR, Annual general meeting, Ovarian cancer, SAN, Platinum, Pharmaceutical industry

NEW YORK and SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the quarter ended March 31, 2024, and highlighted recent corporate accomplishments. "Zentalis continues to advance towards a catalyst-rich period during the second half of 2024 and into 2025, with a clear path to demonstrating the clinical profile of azenosertib, our potentially first-in-class and best-in-class WEE1 inhibitor, across various tumor types," said Kimberly Blackwell, M.D., Chief Executive Officer. "We believe that the data emerging this year and next have the potential to establish azenosertib’s monotherapy activity, differentiated safety and efficacy profile, and its ability to address significant unmet need for patients with serious gynecological cancers. Our clinical development plan remains on track as we work to bring azenosertib to patients living with gynecological cancers and other solid tumors.”

Key Points: 
  • NEW YORK and SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the quarter ended March 31, 2024, and highlighted recent corporate accomplishments.
  • On April 9, 2024, Zentalis presented preclinical data demonstrating that azenosertib exerts synergistic anti-tumor activity with KRASG12C inhibitors at the American Association of Cancer Research (AACR) Annual Meeting.
  • On April 5, 2024, Cam Gallagher was appointed interim Chief Financial Officer while the Company conducts a search for a new Chief Financial Officer.
  • This decrease of $0.7 million was primarily attributable to $0.8 million and $0.7 million decreases in depreciation and other expenses, respectively.